Democrats call for end to generic drug settlements

Share this article:
Sen. Charles Schumer (D-NY) and Rep. Henry Waxman (D-CA) have called on organizations representing innovator and generic drug companies to take a stance against the increase in settlements in which branded companies pay generics firms to keep generic drugs off the market.
The two said such settlements allow brand-name companies to pay generic firms to delay entry of their drugs into the market, decreasing competition and resulting in a drastic increase in the price of prescription drugs.

Schumer and Waxman said the settlements arise in the context of patent infringement lawsuits filed against generic firms.

“In many cases,” they said, “patent settlement agreements can provide great benefit, not only for the parties involved, by allowing them to avoid protracted litigation, but also for consumers, by speeding the entry of generic drugs that might otherwise have been deferred by the litigation.”
But they pointed out that since the late 1990s, settlements have often included agreements by generics firms to stay off the market in exchange for payments from brand-name firms.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...